Boc-MLF |
رقم الكتالوجGC11278
One-Click Copy Product Info
|
Boc-MLF is a tripeptide compound with FPR1 antagonistic activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 67247-12-5
Sample solution is provided at 25 µL, 10mM.
Boc-MLF is a tripeptide compound with FPR1 antagonistic activity. Boc-MLF blocks fMLF binding to FPR1 and inhibits neutrophil chemotaxis, superoxide production, and primary granule exocytosis. Boc-MLF inhibits FPRL1-mediated calcium response. Boc-MLF is used for research on neutrophil inflammation, infection-related inflammation, and premature rupture of membranes[1-4].
In vitro, pretreatment of Neuro2a cells with 5μM Boc-MLF for 30min followed by FPRa14 treatment for 48h reduced FPRa14-induced Neuro2a cell differentiation[5]. Incubation of fMLF-stimulated human neutrophils with 5-10μM Boc-MLF for 5min inhibited neutrophil superoxide production[6]. Pretreatment of U87 cells with 5μM Boc-MLF for 30min followed by 0.1μM fMLF stimulation for 24h. Boc-MLF attenuated fMLF-induced tumorigenic chemotaxis and migration of U87 cells[7].
In vivo, intraperitoneal injection of 25mg/kg Boc-MLF for 8 days in a CT26 cell xenograft BALB/c mouse model treated with neoadjuvant chemoradiotherapy reduced tumor-infiltrating CD8α+ T cells, CD8α+CD44+ T cells, and CD8α+GzmB+ TILs, and weakened the antitumor efficacy of CCRT[8]. Intraperitoneal injection of 5mg/kg Boc-MLF for 2 days in a pregnant SD rat fetal membrane inflammation model promoted an increase in fetal membrane collagen, inhibited amniotic epithelial-mesenchymal transition, and repaired fetal membrane epithelial cell structure[9].
References:[1] Stenfeldt AL, Karlsson J, Wennerås C, et al. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation. 2007 Dec;30(6):224-9.
[2] Xu XW, Zhang Y, Zhao CW, et al. Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. Immunol Lett. 2026 Apr;278:107122.
[3] Gong Z, Yang C, Dai W, et al. Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache. iScience. 2023 Nov 17;26(11):108153.
[4] Chiu I M, Heesters B A, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature. 2013 Sep 5;501(7465):52-57.
[5] Cussell P J G, Howe M S, Illingworth T A, et al. The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA. PLoS ONE. 2019 Jun;14(6):e0217815.
[6] Stenfeldt A L, Karlsson J, Wenneras C, et al. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation. 2007 Dec;30(6):224-229.
[7] Bao Z, Chen K, Krepel S, et al. High glucose promotes human glioblastoma cell growth by increasing the expression and function of chemoattractant and growth factor receptors. Transl Oncol. 2019 Sep;12(9):1155-1163.
[8] Chiang S, Huang K, Chen W, et al. Polymorphism of formyl peptide receptor 1(FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy(CCRT) treatment in locally advanced rectal cancer. Cancer Immunol Immunother. 2021;70(12):2937-2950.
[9] Huang X, Liao E, Liao J, et al. FPR1 antagonist(BOC-MLF) inhibits amniotic epithelial-mesenchymal transition. Current Medical Science. 2024 Feb;44(1):187-194.
| Cell experiment [1]: | |
|
Cell lines |
U87 cells (human glioblastoma cell line) |
|
Preparation Method |
U87 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% FCS at 37°C, 5% CO2 and cultured under normal glucose (5.5mM) or high glucose (25mM). U87 cells cultured in normal glucose or high glucose were pretreated with Boc-MLF (5μM) for 30min before scratching, then fMLF-accelerated wound closure was measured at 24h and photographed for Image J analysis. |
|
Reaction Conditions |
5μM; 30min pretreatment |
|
Applications |
Boc-MLF diminished fMLF-induced U87 cell chemotaxis. Boc-MLF attenuated fMLF-accelerated U87 monolayer wound closure. |
| Animal experiment [2]: | |
|
Animal models |
Sprague-Dawley pregnant rats |
|
Preparation Method |
Pregnant rats at 15 days gestation were intraperitoneally injected with LPS (500μg/kg), and 4h later intraperitoneally injected with Boc-MLF (5mg/kg) for two consecutive days. Rats were sacrificed at 17-19 days of pregnancy for collection of fetal membranes and cardiac blood for Western blotting, immunofluorescence, Masson staining, SEM, and ELISA analyses. |
|
Dosage form |
5mg/kg; i.p.; 2days |
|
Applications |
Boc-MLF promoted an increase in fetal membrane collagen. Boc-MLF inhibited EMT, reduced the weakening of fetal membranes, reversed LPS-induced collapse of fetal membrane epithelial cells, increased intercellular gaps, and mucus attachment, decreased IL-6 levels in cardiac blood. |
| References: [1] Bao Z, Chen K, Krepel S, et al. High Glucose Promotes Human Glioblastoma Cell Growth by Increasing the Expression and Function of Chemoattractant and Growth Factor Receptors. Transl Oncol. 2019 Sep;12(9):1155-1163. [2] Huang X, Liao E, Liao J, et al. FPR1 Antagonist(BOC-MLF) Inhibits Amniotic Epithelial-mesenchymal Transition. Curr Med Sci. 2024 Feb;44(1):187-194. | |
| Cas No. | 67247-12-5 | SDF | |
| Chemical Name | (6R,9S,12S)-12-benzyl-9-isobutyl-2,2-dimethyl-6-(2-(methylthio)ethyl)-4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oic acid | ||
| Canonical SMILES | O=C([C@H](CC(C)C)NC([C@@H](CCSC)NC(OC(C)(C)C)=O)=O)N[C@H](C(O)=O)CC1=CC=CC=C1 | ||
| Formula | C25H39N3O6S | M.Wt | 509.66 |
| الذوبان | Soluble to 2 mg/ml in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9621 mL | 9.8105 mL | 19.6209 mL |
| 5 mM | 392.4 μL | 1.9621 mL | 3.9242 mL |
| 10 mM | 196.2 μL | 981 μL | 1.9621 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)